ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Etoposide

Also written as “etoposide”, “Etoposide (dose level 1)” and “Etoposide (dose level 2)”.

Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Large B-Cell, Diffuse · Lung Neoplasms · Ovarian Neoplasms, led by 20 companies.

Drug pageEtoposide: every studyMany companies study it; this page follows only the 28 they lead. All 598 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 3, 202028 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only41 open or runningphase 3since Dec 3, 2020Mar 12, 2018none ahead
Hoffmann-La Rocheits history only40 open or runningphase 3since Jul 19, 2019Oct 20, 2008none ahead
Bristol-Myers Squibbits history only20 open or runningphase 2since Jan 7, 2021Feb 20, 2019none ahead
Jiangsu HengRui Medicineits history only20 open or runningphase 3since Jun 24, 2019Jun 24, 2019none ahead
Amgenits history only10 open or runningphase 2since Nov 6, 2013Nov 6, 2013none ahead
BeOne Medicinesits history only10 open or runningphase 2since Feb 8, 2018Feb 8, 2018none ahead
BioNTechits history only11 open or runningphase 2since Jun 3, 2024Jun 3, 2024Jun 2027phase 2 · NCT06449209
Boehringer Ingelheimits history only11 open or runningphase 3since Mar 4, 2026Mar 4, 2026Sep 9, 2028phase 3 · NCT07472517
Eli Lillyits history only10 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead
EpicentRxits history only10 open or runningphase 2since Jun 29, 2015Jun 29, 2015none ahead
GlaxoSmithKline10 open or runningphase 3since Aug 14, 2002Aug 14, 2002none ahead

Also a collaborator on its studies: Genelux.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2002First study: phase 3 study in Small Cell Lung CarcinomaFirst studyNCT00043927 · 760 enrolled · United States, Austria, Belgium and more
  2. Dec 9, 2016Named etoposideINNProposed as its International Nonproprietary Name in WHO's List 116

TargetBeta

TOP2A →TOP2B →read by rule
“DNA topoisomerase II inhibitor”ChEMBL 37, by rule

Studies

The one study GlaxoSmithKline leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more3CompletedJan 2004760

How it is read

Names in the registry

  • “Etoposide”, 18 entries
  • “etoposide”, 3 entries
  • “Etoposide (dose level 1)”, 1 entry
  • “Etoposide (dose level 2)”, 1 entry
  • “recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.